Effectiveness of neurofeedback versus medication for attention-deficit/hyperactivity disorder

被引:14
|
作者
Sudnawa, Khemika Khemakanok [1 ,5 ]
Chirdkiatgumchai, Vilawan [1 ]
Ruangdaraganon, Nichara [1 ]
Khongkhatithum, Chaiyos [2 ]
Udomsubpayakul, Umaporn [3 ]
Jirayucharoensak, Suwicha [4 ]
Israsena, Pasin [4 ]
机构
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Dev & Behav Pediat,Dept Pediat, Bangkok, Thailand
[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Pediat Neurol,Dept Pediat, Bangkok, Thailand
[3] Ramathibodi Hosp, Sect Clin Epidemiol & Biostat, Bangkok, Thailand
[4] Natl Elect & Comp Technol Ctr, Pathum Thani, Thailand
[5] Phramongkutklao Hosp, Div Dev & Behav Pediat, Bangkok, Thailand
关键词
attention-deficit; hyperactivity disorder; medication; methylphenidate; neurofeedback; randomized controlled trial; DEFICIT-HYPERACTIVITY DISORDER; PSYCHOMETRIC PROPERTIES; RATING-SCALE; ADHD; CHILDREN; METAANALYSIS; ADOLESCENTS; EEG;
D O I
10.1111/ped.13641
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundNeurofeedback (NF) is an operant conditioning procedure that trains participants to self-regulate brain activity. NF is a promising treatment for attention-deficit/hyperactivity disorder (ADHD), but there have been only a few randomized controlled trials comparing the effectiveness of NF with medication with various NF protocols. The aim of this study was therefore to evaluate the effectiveness of unipolar electrode NF using theta/beta protocol compared with methylphenidate (MPH) for ADHD. MethodsChildren with newly diagnosed ADHD were randomly organized into NF and MPH groups. The NF group received 30 sessions of NF. Children in the MPH group were prescribed MPH for 12 weeks. Vanderbilt ADHD rating scales were completed by parents and teachers to evaluate ADHD symptoms before and after treatment. Student's t-test and Cohen's d were used to compare symptoms between groups and evaluate the effect size (ES) of each treatment, respectively. ResultsForty children participated in the study. No differences in ADHD baseline symptoms were found between groups. After treatment, teachers reported significantly lower ADHD symptoms in the MPH group (P = 0.01), but there were no differences between groups on parent report (P = 0.55). MPH had a large ES (Cohen's d, 1.30-1.69), while NF had a moderate ES (Cohen's d, 0.49-0.68) for treatment of ADHD symptoms. ConclusionNeurofeedback is a promising alternative treatment for ADHD in children who do not respond to or experience significant adverse effects from ADHD medication.
引用
收藏
页码:828 / 834
页数:7
相关论文
共 50 条
  • [31] Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts
    Chang, Zheng
    Quinn, Patrick D.
    O'Reilly, Lauren
    Sjolander, Arvid
    Hur, Kwan
    Gibbons, Robert
    Larsson, Henrik
    D'Onofrio, Brian M.
    BIOLOGICAL PSYCHIATRY, 2020, 88 (06) : 452 - 458
  • [32] Current Status of Neurofeedback for Attention-Deficit/Hyperactivity Disorder
    Nicholas Lofthouse
    L. Eugene Arnold
    Elizabeth Hurt
    Current Psychiatry Reports, 2012, 14 : 536 - 542
  • [33] Neurofeedback in Attention-Deficit/Hyperactivity Disorder: Efficacy Reply
    Cortese, Samuele
    Brandeis, Daniel
    Holtmann, Martin
    Sonuga-Barke, Edmund J. S.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (12) : 1092 - 1093
  • [34] Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan
    Wang, Liang-Jen
    Lee, Sheng-Yu
    Yuan, Shin-Sheng
    Yang, Chun-Ju
    Yang, Kang-Chung
    Lee, Tung-Liang
    Shyu, Yu-Chiau
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (01) : 45 - 53
  • [35] Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study
    Ricketts, Emily J.
    Sturm, Alexandra
    McMakin, Dana L.
    McGuire, Joseph F.
    Tan, Patricia Z.
    Smalberg, Fallon B.
    McCracken, James T.
    Colwell, Christopher S.
    Piacentini, John
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (10) : 690 - 698
  • [36] Medication Costs to Private Insurers of Diversion of Medications for Attention-Deficit Hyperactivity Disorder
    Aldridge, Arnie P.
    Kroutil, Larry A.
    Cowell, Alexander J.
    Reeves, Daniel B.
    Van Brunt, David L.
    PHARMACOECONOMICS, 2011, 29 (07) : 621 - 635
  • [37] Familial aggregation of attention-deficit/hyperactivity disorder
    Chen, Qi
    Brikell, Isabell
    Lichtenstein, Paul
    Serlachius, Eva
    Kuja-Halkola, Ralf
    Sandin, Sven
    Larsson, Henrik
    JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2017, 58 (03) : 231 - 239
  • [38] Treatment of Attention-Deficit Hyperactivity Disorder in Athletes
    Kutcher, Jeffrey S.
    CURRENT SPORTS MEDICINE REPORTS, 2011, 10 (01) : 32 - 36
  • [39] Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: A comparison with methylphenidate
    Fuchs, T
    Birbaumer, N
    Lutzenberger, W
    Gruzelier, JH
    Kaiser, J
    APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK, 2003, 28 (01) : 1 - 12
  • [40] Sex Differences in Effectiveness of Extended-Release Stimulant Medication among Adolescents with Attention-Deficit/Hyperactivity Disorder
    Mikami, Amori Yee
    Cox, Daniel J.
    Davis, Margaret T.
    Wilson, H. Kent
    Merkel, R. Lawrence
    Burket, Roger
    JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS, 2009, 16 (03) : 233 - 242